search
Back to results

Comparison Study With E-DO in Chronic Hand Dermatitis

Primary Purpose

Chronic Hand Dermatitis

Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
E-DO
Placebo
Sponsored by
HenKan Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Hand Dermatitis focused on measuring chronic hand dermatitis, research study, E-do, HK-03

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males or females aged 20 years of age or above;
  • Patients must have chronic hand dermatitis based upon clinical diagnosis at least mild dermatitis of the both hands at baseline, as defined by an Investigator Global Assessment score of 2 (mild) to 5 (very severe);
  • Patients must have been informed of the study procedures and therapies and have given their written informed consent.

Exclusion Criteria:

  • Women who are pregnant or who are breast-feeding;
  • Patients who have received systemic corticosteroids (i.e., oral, intravenous, intra-articular, rectal, intramuscular) within one month prior to first application of study medication;
  • Patients who have received phototherapy (e.g., UVB, PUVA) or systemic therapy (e.g., immunosuppressants, cytostatics) known or suspected to have an effect on hand dermatitis within one month prior to first application of study medication;
  • Patients who are treated with topical therapy (e.g., tar, topical corticosteroids) known or suspected to have an effect on hand dermatitis within 7 days prior to first application of study medication;
  • Patients who have a diagnosis on the hands of active atopic dermatitis, dyshidrotic eczema, psoriasis, urticaria, active fungal or bacterial infection, or identified allergic contact dermatitis (e.g., poison ivy dermatitis)
  • Patients with hypersensitivity to vitamin B, vitamin C, vitamin E, beta-carotene.

Sites / Locations

  • Department of Dermatology, NTUH

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

A

B

Arm Description

applied on one hand

applied on the other hand

Outcomes

Primary Outcome Measures

The therapeutic response rate (clear or almost clear) base on Investigator Global Assessment (IGA)

Secondary Outcome Measures

The proportion of the patients with at least 50% improvement (clinically significant response) base on the patient's global assessment (PaGA)
The percent change in the HEAS (Hand Eczema Area and Severity Score) from baseline to post-treatment.
The change of pruritus score and pain score from baseline to post-treatment
The change in the degree of moisture on the skin's surface, and the water evaporation on skin surfaces by TEWL, and the QOL scores from baseline to the end of study.
The safety and tolerability of E-DO including AE/SAE report

Full Information

First Posted
November 8, 2007
Last Updated
January 9, 2009
Sponsor
HenKan Pharmaceutical Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT00556855
Brief Title
Comparison Study With E-DO in Chronic Hand Dermatitis
Official Title
A 4-Week Randomized, Double-Blind, Placebo-Controlled, Right-Left Comparison Study With E-DO in Chronic Hand Dermatitis
Study Type
Interventional

2. Study Status

Record Verification Date
January 2009
Overall Recruitment Status
Completed
Study Start Date
December 2007 (undefined)
Primary Completion Date
July 2008 (Actual)
Study Completion Date
July 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
HenKan Pharmaceutical Co., Ltd.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to evaluate the topical E-DO in patients with Chronic Hand Dermatitis (fu kuei shou).
Detailed Description
Hand dermatitis, also called fu kuei shou, is a skin condition in which the hands develop a rash and become red, dry, cracked, and inflamed. This is a very common occuring in about 10% of women and 4% of men. The condition can eventually cause pain on contact with even simple solutions such as water. Hand dermatitis is particularly common in industries involving cleaning, catering, metalwork, hairdressing, healthcare and mechanical work, and is often difficult to be treated effectively. Some patients develop varying levels of disability due to lack of acceptable effective treatments and may be forced to change occupations in order to achieve relief. Primary treatment for hand dermatitis is typically topical corticosteroids, especially when the offending agent(s) cannot be identified or avoided. However, patients may eventually develop tachyphylaxis to the anti-inflammatory activity of mid-potency or high-potency topical corticosteroids and patients with severe, chronic involvement may often be less likely to respond. Potential topical alternatives to corticosteroids include psoralen plus ultraviolet (PUVA), but the phototherapies are inconvenient because multiple clinical visits are required and hand phototherapy units may not be available. Moisturizers have been found to help restore the skin barrier providing a protective layer on surface of the skin to trap water and prevent the penetration of irritants and allergens. An emollient cream is superior in trapping the moisture within the skin. Emollients may form a covering film, which acts as a barrier for chemicals from the exterior and which restricts the loss of water and other essential substances from the interior. E-DO gel is a potential agent for revitalizing our skin cells so that regain their moisture retention capacity. E-DO has known significant improvements in wound healing and the inhibition of Staphylococcus aureus and Propionibacterium acnes. This pilot research trial will investigate the effect of topical E-DO for patients with hand dermatitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Hand Dermatitis
Keywords
chronic hand dermatitis, research study, E-do, HK-03

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
67 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
applied on one hand
Arm Title
B
Arm Type
Placebo Comparator
Arm Description
applied on the other hand
Intervention Type
Other
Intervention Name(s)
E-DO
Other Intervention Name(s)
HK-03
Intervention Description
topical lotion, once daily (evening), total duration: 4 weeks
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
Vehicle
Intervention Description
topical lotion, once daily (evening), total duration: 4 weeks
Primary Outcome Measure Information:
Title
The therapeutic response rate (clear or almost clear) base on Investigator Global Assessment (IGA)
Time Frame
at Week 4 (or at time of early discontinuation)
Secondary Outcome Measure Information:
Title
The proportion of the patients with at least 50% improvement (clinically significant response) base on the patient's global assessment (PaGA)
Time Frame
at Week 4 (or at time of early discontinuation)
Title
The percent change in the HEAS (Hand Eczema Area and Severity Score) from baseline to post-treatment.
Time Frame
during 4 Weeks
Title
The change of pruritus score and pain score from baseline to post-treatment
Time Frame
during 4 weeks
Title
The change in the degree of moisture on the skin's surface, and the water evaporation on skin surfaces by TEWL, and the QOL scores from baseline to the end of study.
Time Frame
End of study (4 weeks)
Title
The safety and tolerability of E-DO including AE/SAE report
Time Frame
during 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females aged 20 years of age or above; Patients must have chronic hand dermatitis based upon clinical diagnosis at least mild dermatitis of the both hands at baseline, as defined by an Investigator Global Assessment score of 2 (mild) to 5 (very severe); Patients must have been informed of the study procedures and therapies and have given their written informed consent. Exclusion Criteria: Women who are pregnant or who are breast-feeding; Patients who have received systemic corticosteroids (i.e., oral, intravenous, intra-articular, rectal, intramuscular) within one month prior to first application of study medication; Patients who have received phototherapy (e.g., UVB, PUVA) or systemic therapy (e.g., immunosuppressants, cytostatics) known or suspected to have an effect on hand dermatitis within one month prior to first application of study medication; Patients who are treated with topical therapy (e.g., tar, topical corticosteroids) known or suspected to have an effect on hand dermatitis within 7 days prior to first application of study medication; Patients who have a diagnosis on the hands of active atopic dermatitis, dyshidrotic eczema, psoriasis, urticaria, active fungal or bacterial infection, or identified allergic contact dermatitis (e.g., poison ivy dermatitis) Patients with hypersensitivity to vitamin B, vitamin C, vitamin E, beta-carotene.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Chia-Yu Chu, MD, PhD
Organizational Affiliation
Department of Dermatology, Nation Taiwan University Hopital, R.O.C.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Dermatology, NTUH
City
Taipei
ZIP/Postal Code
100
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

Comparison Study With E-DO in Chronic Hand Dermatitis

We'll reach out to this number within 24 hrs